US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) has made clear its opposition to the drug price-setting provisions in the Biden administration’s Inflation Reduction Act (IRA).
But the group’s attempts to stop the price-curbing measures have suffered a setback, with a federal judge on Monday throwing out PhRMA’s lawsuit in the District Court for the Western District of Texas.
PhRMA, alongside the National Infusion Center Association (NICA) and the Global Colon Cancer Association, filed a complaint in the court last year asserting that the price-setting provisions in the IRA are unconstitutional.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze